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A recent study disclosed that breast cancer cases with low ‘tau’ expression can predict susceptibility to Paclitaxel administration. In
the current study, the clinical significance of tau expression in gastric cancer cases was established by identifying candidates with
Paclitaxel administration. Tissue specimens from 20 cases of in-operable or noncuratively resected gastric cancer were examined.
Subsequent to the administration of 80mgm
 2 of Paclitaxel in six 3-h intravenous infusions, the clinical effectiveness of Paclitaxel was
evaluated by the size of metastatic lesions with computed tomography. The status of the tau expression was determined by
immunohistochemistry. Based on a previously reported classification scheme, six were classified as tau-negative expression (0, 1þ)
cases and 14 were classified as tau-positive expression (2þ,3þ) cases. All six (100%) cases of tau-negative expression showed a
favourable response (partial response or minor response) to Paclitaxel administration. However, 12 (86%) of the 14 cases of tau-
positive expression showed progressive disease (n¼11) or no change (n¼1) after Paclitaxel administration. The serum
carcinoembryonic antigen values of the six cases of tau-negative expression were markedly decreased in comparison to the 14 tau-
positive cases. These data indicate that tau-negative expression can be used to select gastric cancer patients, which will favourably
respond to Paclitaxel treatment.
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It has been more than 10 years since Paclitaxel emerged as a
successful drug for the treatment of advanced gastric cancer.
However, the overall response rate to this drug remains low. The
solitary administration of Paclitaxel is insufficient for clinical
benefit in comparison to combination treatments with other drugs,
such as anthracycline, 5-fluorouracil (FU), and irinotecan (Park
et al, 2004). In fact, combination therapy with anthracycline and
Paclitaxel improved disease-free survival (Henderson et al, 2003).
On the other hand, a Phase I study of Paclitaxel revealed a high
incidence of alopecia or grade 1–2 leukocytopenia (Cascinu et al,
1997). Therefore, if appropriate candidates for Paclitaxel admin-
istration can be identified at the time of diagnosis, a high
antitumour effect and reduced side effects may improve the
therapeutic index of the drug.
Recently, Rouzier et al reported that tissue arrays from 122
independent but similarly treated breast cancer patients were used
for validation by immunohistochemistry (IHC). In total, 74% of
pathologically complete response (pCR) cases were tau protein
negative. In multivariate analysis, nuclear grade (Po0.01), age
o50 (P¼0.03), and tau-negative status (P¼0.04) were indepen-
dent predictors of pCR. The authors also showed decreased
Paclitaxel binding and reduced microtubule polymerisation in
breast cancer cells after preincubation of tubulin with tau protein
(Rouzier et al, 2005).
The purpose of this study was to clarify the significance of tau
expression in gastric cancer from the view point of Paclitaxel
administration.
PATIENTS AND METHODS
Patients and samples
A total of 20 cases of advanced and nonresectable gastric cancer
with Paclitaxel administration were used for this study. The
average age at treatment was 66 years, ranging from 52 to 81 years
of age. There were 14 male and six female patients. In all, 14
patients were treated at Kyushu University Hospital at Beppu, and
six were treated at Kyushu Central Hospital. Gastric cancer tissues
and the corresponding normal tissues were obtained from nine
cases of palliative surgery (noncurative operations). Biopsy
specimens were obtained from eight recurrent cases and three
inoperable cases. Recurrent disease was recognised in the liver,
lungs, abdominal lymph nodes, and peritoneal dissemination.
Histological findings were as follows: nine cases of differentiated
type (two well-differentiated adenocarcinomas and seven moder-
ately differentiated adenocarcinomas); nine of the undifferentiated
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stype (five poorly differentiated adenocarcinomas and four signet-
ring cell carcinomas); and two cases of mucinous adenocarcinoma
(Table 1).
Chemotherapy regimens and evaluations
Paclitaxel was administered as the first-line chemotherapy in 10
(50%) of the 20 cases, and there was no deviation of the first-line-
treated number of cases between the six cases of tau-negative
expression and the 14 cases of tau-positive expression. The
remaining 10 cases were treated by 5-FU plus cisplatin followed by
Paclitaxel as the second-line chemotherapy. A 3-h intravenous
infusion of Paclitaxel (80mgm
 2) was given on days 1, 8, and 15,
and was repeated twice every 4 weeks (Yeh et al, 2005). Tumour
response was evaluated by measuring the serum level of
carcinoembryonic antigen (CEA) and the size of the metastatic
lesions with computed tomography (CT) 2 months after the initial
administration of Paclitaxel. Responses were defined as complete
(CR, no clinical/radiographic detectable disease), partial (PR,
4/¼50% reduction in disease), minor (MR, o50% reduction),
no change (NC), or progressive disease (PD).
IHC
Sections (4mm) were prepared for tissue slides. Antigen retrieval
was performed by boiling in citrate buffer (pH 6.0) for 10min in a
microwave oven after deparaffinisation. Nonspecific binding was
blocked by incubating sections in *PBS containing 1% normal
bovine serum and 0.3% Triton-X 100. The slides were rinsed three
times with PBS for 3min and incubated with an anti-TAU-1
monoclonal antibody (5mgml
 1; clone #PC1C6) (Cedarlane,
Hornby, Ontario, Canada) diluted in PBS containing 1% normal
bovine serum (Binder et al, 1985). The slides were again washed
with PBS, changing the solution three times over a 3-min period,
after which detection was performed with a standard secondary
antibody system (Taylor, 1978; Hsu et al, 1981; Falini and Taylor,
1983). Sections of normal breast were used as external reference
control for staining and scoring. The previous reported IHC
scoring was followed: 0, no staining; 1þ, less staining than normal
epithelium; 2þ, similar to normal epithelium; 3þ, uniform
staining more intense than normal cells. In accord with the
previous study, cases with 0 or 1þ staining intensity were
considered tau negative, and tumours with 2þ/3þ staining were
considered tau positive (Rouzier et al, 2005).
Statistical analysis
Each clinicopathological variable was compared between the tau-
positive and -negative expression groups, and evaluated with
Fisher’s exact test.
RESULTS
As shown in Figure 1, according to the tau protein expression
pattern in the cancerous and corresponding normal tissues, two,
12, four, and two cases showed 0, 1þ,2 þ, and 3þ staining,
respectively. The clinicopathological variables between 14 tau-
positive cases (3þ,2 þ) and six tau-negative cases (0, 1þ) are
summarized in Table 1. There was no significant difference
between the two groups with respect to sex, histology, or
pretreatment status. However, there was a significant difference
between the clinical effectiveness of Paclitaxel and tau expression
status. All six (100%) cases of tau-negative expression responded
Table 1 Relationship between tau expression and the clinical usefulness of paclitaxel in 20 paclitaxel-administrated cases of gastric cancer
Tau expression
Variables n Low (0, 1+) (n¼6) High (2+, 3+) (n¼14) P-value
Clinicopathologhical variables
Sex np
Male 14 4 10
Female 6 2 4
Histology
a np
Differentiated type 9 2 7
Undifferentiated type 9 2 7
Other 2 2 0
Pretreatment
5-FU+cisplatin 10 4 6
None 10 2 8
Clinical effectiveness
Average (range) of CEA altered by Paclitaxel administration 98% (69–140) 129% (21–237) np
Clinical effectiveness Po0.01
b
Partial response (PR) 2 1
Mild response (MR) 9 4 1
No change (NC) 01
Progressive disease (PD) 11 0 11
Improved symptoms
Ascites 43
Appetite loss 33
Adverse effects
c
Leukocytopenia 15 5 10 np
Alopecia 12 4 8 np
aDifferentiated type: well-differentiated and moderately differentiated adenocarcinomas. Undifferentiated type: signet ring cell and poorly differentiated adenocarcinomas. Other:
mucinous adenocarcinoma.
bThere is a significant correlation between tau expression and response to Paclitaxel. All six (100%) cases of low expression were responsive (PR,
MR), whereas 12 (86%) of 14 cases of high expression were unresponsive (PD, NC).
cBone marrow suppression was defined as a decrease in neutrophil number in the
peripheral blood to less than 1500mm
 3. Apetite loss was assessed within 2 days of Paclitaxel administration. 5-FU¼5-fluorouracil; CEA¼carcinoembryonic antigen.
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sto Paclitaxel administration (PR, MR), but 12 (86%) of the 14 tau-
positive cases showed no response (PD, NC) to Paclitaxel.
In addition, the serum CEA value was examined as a comparison
of the clinical effectiveness between positive and negative tau
expression. The difference did not reach statistical significance;
however, the serum CEA value decreased in five (83%) of six tau-
negative cases after Paclitaxel administration. On the other hand, it
was increased in 10 (71%) of 14 tau-positive cases after Paclitaxel
administration. As for the alteration of the practical CEA value
after Paclitaxel administration, the six patients with tau-negative
expression reduced the value to 98% of the pretreatment value,
whereas it was increased by 129% in the 14 tau-positive patients.
Computed tomography evaluation of the six tau-negative cases
revealed that two cases showed a reduction in tumour size in the
minor curvature of the stomach (MR), one case exhibited ascites
elimination (PR), and the remaining three cases had a reduction in
the size of paraaortic lymph node swelling (one PR and two MR)
with the administration of Paclitaxel.
In addition, adverse events resulting from the administration of
Paclitaxel were investigated. Leukocytopenia defined as grade 2 or
3 (500mm
 3oneutrophilo1500mm
 3) was observed in five
(83%) out of six cases of tau-negative expression and in 10
(71%) out of 14 cases of tau-positive expression, with no
significant difference between the groups. There was also no
significant difference between the groups regarding the occurrence
of alopecia, which was recognized in four (67%) out of six of those
with tau-negative expression and eight (57%) out of 14 cases with
tau-positive expression.
Furthermore, a comparison of the improvement of symptoms
after Paclitaxel administration in tau-negative cases and tau-
positive cases was as follows: vanishing ascites were observed in
four (67%) out of six tau-negative cases and four (29%) out of 14
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Figure 1 Representative Tau expression pattern in gastric cancer cases for the IHC score (3þ,2þ,1þ and 0), whereas the right-hand side indicates
the haematoxylin eosin staining ( 40 magnification). (A)3 þ: There is strong granular staining in the cytoplasm of cancer cells obtained from biopsy
specimens, moderately differentiated adenocarcinoma. This case was inoperable owing to the pleural effusions and the mediastinum lymph node metastases;
a Paclitaxel nonresponsive case (PD). (B)2þ: Both nuclei and cytoplasm of the cancer cells are strongly positive. Normal mucosal glands are also positive.
This case originated from a resected specimen of signet ring cell carcinoma after distal gastrectomy. A noncurative or a palliative operation was performed
because of the dissemination of cancer cells into the retroperitoneum; a Paclitaxel nonresponsive case (PD). (C)1þ: A signet ring cell carcinoma case with
positive tau expression is observed both in normal and tumour tissues. However, normal cells have a stronger signal than those of the tumorous tissue. No
remarkable change was observed after Paclitaxel administration (NC). (D) 0: While the normal gastric glands (right) are strongly stained, the signet-ring type
cancer cells (left) are completely negative. This case was partially responsive case (PR).
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stau-positive cases. In addition, appetite loss decreased in three
(50%) out of six and three (21%) out of 14 cases of tau positive.
DISCUSSION
Various molecules have been reported as markers for prediction of a
high level of sensitivity to Paclitaxel. Vikhanskaya et al (1998)
reported that the inactivation of p53 is susceptible to Paclitaxel in
ovarian cancer (Rouzier et al,2 0 0 5 ) ,a n dR e i n e c k eet al (2000a,b)
described the expression and function of P-glycoprotein in renal cell
carcinoma. Moreover, the overexpression of antiapoptotic genes
(Wang et al, 2005), the upregulation of cyclin A (Takahashi et al,
2005), the overexpression of oestrogen receptor (Dougherty et al,
2004), and the reduced expression of tau (Rouzier et al, 2005) have
all been reported as Paclitaxel susceptibility markers in breast
cancer. As for colorectal cancers, the expression of MDR-1, bcl-2,
and bax each contribute to Paclitaxel sensitivity (Sharma et al, 2000).
In the current study, we focus on tau expression as the
susceptible marker for Paclitaxel against gastric cancer, because,
there have been no definitive studies of Paclitaxel sensitivity
markers in gastric cancer. In logical consideration, we expect that
tau can be a suitable powerful marker for the microtubulising
agent, Paclitaxel. Because tau binds to microtubules strongly
without Paclitaxel, whereas microtubules assembled in the
presence of Paclitaxel show moderate binding affinity and rapid
dissociation kinetics of tau protein (Rouzier et al, 2005).
Consistent with the report of breast cancer, we found that gastric
cancer cases with low levels of tau expression also indicate a higher
susceptibility to Paclitaxel treatment. All six (100%) cases of low
tau expression not only had a favourable clinical response but also
showed an improvement of clinical symptoms, such as ascites and
appetite loss due to Paclitaxel administration. Only two (14.3%) of
the 14 cases with high tau expression showed a similar response.
However, in spite of the improved effectiveness, side effects such
as bone marrow suppression, alopecia, and appetite loss (recorded
within 2 days after Paclitaxel administration) were observed
equally between patients of low and high tau expression. This
observation indicates that tau expression status cannot become an
indicator of adverse effects due to Paclitaxel. Therefore, other
indicators, such as single-nucleotide polymorphisms in the
genomic region, must be used to predict which patients are at
high risk for severe adverse effects. Studies are ongoing in an effort
to find these markers.
As Rouzier et al also described, low tau expression renders
microtubules more vulnerable to Paclitaxel and makes breast
cancer cells hypersensitive to this drug. They postulated that tau
could be a molecular target therapy to elevate sensitivity to
Paclitaxel by the inhibition of tau expression in breast cancer cases
(Rouzier et al, 2005). We propose that tau inhibition would also
improve the clinical effectiveness of Paclitaxel in gastric cancer
cases.
In conclusion, low tau expression denotes a higher susceptibility
to Paclitaxel treatment in gastric cancer. This finding suggests that
tau expression could be used at diagnosis to select patients for
whom Paclitaxel treatment would be most beneficial. However,
many more cases will have to be examined before tau expression
can be applied to practical clinical treatment.
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